Thursday, February 6, 2025

Foundation Fighting Blindness to Host Free Webinar on Gene Therapies for Inherited Retinal Diseases

The free, online event at 7 p.m. ET on March 13, will review several topics, including: Viral delivery systems, surgical techniques, current clinical trials and endpoints, inflammation management, and future directions. 

Wednesday, February 5, 2025

EyePoint Reports Positive Results from DME Trial

Six-month data from the phase 2 VERONA trial shows Duravyu extended treatment intervals and improved vision for diabetic macular edema patients.

Tuesday, February 4, 2025

FDA Clears Susvimo for the Treatment of DME

Genentech’s refillable implant is the first continuous-delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema.

Monday, February 3, 2025

New Test Detects Parent-of-Origin in Hereditary Eye Cancer

Origin matters for this hereditary ocular cancer because researchers found that male and female copies of the mutation are associated with different disease trajectories, and so would likely influence physicians' treatment recommendations.

Monday, February 3, 2025

BVI Medical Launches EyeXchange Solutions Educational Platform for Ophthalmic Surgeons

EyeXchange Solutions connects experienced and emerging surgeons across cataract, glaucoma, and retina specialties to share insights, refine techniques, and address complex cases. 

Thursday, January 30, 2025

Norlase Receives 510(k) Clearance for LYNX Pattern Scanning Laser Indirect Ophthalmoscope

Norlase has announced the immediate commercial launch and FDA 510(k) clearance and CE Mark for LYNX, the company’s pattern scanning laser indirect ophthalmoscope. 

Thursday, January 30, 2025

AI Optics Receives FDA 510k Clearance for Sentinel Camera Handheld Retinal Imaging System

AI Optics' Sentinel Camera is a handheld retinal imaging system that captures high-quality images of the human eye, and is designed to be easy to use and support non-dilated imaging. 

Thursday, January 30, 2025

PulseSight Therapeutics Initiates Clinical Plan of Transferrin Vectorized Therapy for Dry AMD and GA

PulseSight Therapeutics announced it has submitted a Clinical Trial Authorization to France's regulatory agency for PST-611, a first-in-class non-viral vectorized therapy for the treatment of dry age-related macular degeneration and geographic atrophy.

Thursday, January 30, 2025

Ocular Therapeutix Shares SOL-R Enrollment Progress, Next Steps for Axpaxli in Non-Proliferative Diabetic Retinopathy

Ocular Therapeutix has outlined the clinical progress across its registrational program for Axpaxli in wet age-related macular degeneration (wet AMD), plans to advance Axpaxli in non-proliferative diabetic retinopathy (NPDR), and the company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference. 

Thursday, January 30, 2025

Harrow and Cencora Partner to Launch Harrow Cares Program

According to Harrow, the Harrow Cares program ensures seamless enrollment, rapid access to therapy, and personalized support, enabling retina providers to confidently utilize Iheezo and Triesence in their practices.

Wednesday, January 22, 2025

MeiraGTx Receives Rare Pediatric Disease Designation from FDA

The designation is for the company's AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1). It makes the fourth Rare Pediatric Disease Designation MeiraGTx has received for inherited retinal diseases.

Tuesday, January 21, 2025

Nacuity Pharmaceuticals Granted FDA Fast Track Designation for NPI-001 Tablets for Retinitis Pigmentosa

Fast Track Designation represents an objective assessment by the FDA for the potential of NPI-001 tablets as a treatment for retinitis pigmentosa, the company said. 

Wednesday, January 15, 2025

GenSight Reports 5-year Lumevoq Outcomes for LHON Patients

Patients with Leber hereditary optic neuropathy due to the MT-ND4 gene variant demonstrated sustained bilateral improvement in visual acuity and a favorable safety profile 5 years after treatment. 

Wednesday, January 15, 2025

City Therapeutics Enters Into Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for GA

Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Wednesday, January 15, 2025

Inflammasome Therapeutics Reports Topline 3-month Data from Clinical Trial of Dual Inflammasome Inhibitor, K8, in GA

In a US clinical trial of five patients with bilateral geographic atrophy, sustained-release intravitreous implants of K8 were well tolerated, with no drug-related ocular or systemic serious adverse events.

Tuesday, January 14, 2025

Data Show Implantable Telescope Improves Vision in Advanced AMD

Samsara Vision reported intermediate-term visual and safety outcomes of a study of the SING IMT in patients 6 months post-surgery.

Tuesday, January 14, 2025

Interim Results Reported From 4D-150 SPECTRA Clinical Trial in DME

The 3E10 vg/eye dose demonstrated notable efficacy, achieving sustained visual acuity gains.

Monday, January 13, 2025

Bausch + Lomb Acquires Whitecap Biosciences

With innovative therapies addressing glaucoma and geographic atrophy currently in development, the acquisition of Whitecap Bioscience's strengthens B + L’s expanding clinical-stage pipeline. 

Tuesday, January 7, 2025

Sozinibercept Shows Efficacy as DME Treatment

Recently published results of a phase 1 study support its potential in combination with aflibercept.

Tuesday, January 7, 2025

Canyon Labs Acquires iuvo BioScience’s Lab Division

The deal allows each company to focus on strengths.

Monday, January 6, 2025

Regeneron Acquires UK Biotech Firm Oxular

Monday, January 6, 2025

Cencora Finalizes RCA Acquisition

Monday, January 6, 2025

Smart Glasses for Vision Loss Debut at CES 2025

SolidddVision’s vision correction technology can improve sight for patients with macular degeneration and other conditions.

Monday, January 6, 2025

OCS-05 Shows Efficacy in Treating Acute Optic Neuritis

ACUITY trial reveals potential to improve retinal structure and vision.

Monday, January 6, 2025

EssilorLuxottica to Acquire Espansione Group

The deal to acquire the Italian company expands Essilor’s medical technology portfolio.

Monday, January 6, 2025

Galimedix Begins Trial for Dry AMD Eye Drops

The phase 2 study will examine GAL-101’s potential to slow the growth of geographic atrophy lesions.